1py5: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
Line 1: Line 1:
[[Image:1py5.gif|left|200px]]
{{Seed}}
[[Image:1py5.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1py5|  PDB=1py5  |  SCENE=  }}  
{{STRUCTURE_1py5|  PDB=1py5  |  SCENE=  }}  


'''Crystal Structure of TGF-beta receptor I kinase with inhibitor'''
===Crystal Structure of TGF-beta receptor I kinase with inhibitor===




==Overview==
<!--  
We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.
The line below this paragraph, {{ABSTRACT_PUBMED_15177479}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15177479 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15177479}}


==Disease==
==Disease==
Line 31: Line 35:
[[Category: Receptor i]]
[[Category: Receptor i]]
[[Category: Tgf-beta]]
[[Category: Tgf-beta]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 05:38:12 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 12:13:08 2008''
Retrieved from "https://proteopedia.org/1py5"